No headlines found.
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Globe Newswire (Thu, 28-Mar 7:00 AM ET)
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Globe Newswire (Tue, 26-Mar 8:00 AM ET)
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Globe Newswire (Mon, 4-Mar 7:00 AM ET)
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Globe Newswire (Wed, 7-Feb 7:00 AM ET)
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Globe Newswire (Fri, 19-Jan 4:15 PM ET)
Globe Newswire (Wed, 17-Jan 4:30 PM ET)
Globe Newswire (Wed, 3-Jan 7:00 AM ET)
Apollomics to Present at the 2024 Biotech Showcase
Globe Newswire (Tue, 2-Jan 4:30 PM ET)
Apollomics - Warrant trades on the stock market under the symbol APLMW.
As of March 28, 2024, APLMW stock price climbed to $0.03 with 5,700 million shares trading.
APLMW has a beta of -2.36, meaning it tends to be less sensitive to market movements. APLMW has a correlation of 0.03 to the broad based SPY ETF.
APLMW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
APLMW support price is $.01 and resistance is $.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLMW stock will trade within this expected range on the day.